Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
作者信息
Nowak Anna K
机构信息
Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia; ; School of Medicine and Pharmacology, University of Western Australia, M503, 35 Stirling Highway Crawley, WA 6009, Australia; ; National Research Centre for Asbestos Related Diseases, M503, 35 Stirling Highway Crawley, WA 6009, Australia.
出版信息
Ann Cardiothorac Surg. 2012 Nov;1(4):508-15. doi: 10.3978/j.issn.2225-319X.2012.10.05.
Abstract
摘要
相似文献
1
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.恶性胸膜间皮瘤的化疗：当前治疗方法综述与未来展望
Ann Cardiothorac Surg. 2012 Nov;1(4):508-15. doi: 10.3978/j.issn.2225-319X.2012.10.05.
2
Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.一名儿童的恶性胸膜间皮瘤：采用ICE-WAC化疗方案实现长期生存
Turk J Pediatr. 2002 Jul-Sep;44(3):244-7.
3
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.恶性胸膜间皮瘤的新辅助化疗和胸膜外全肺切除术联合或不联合半胸部放疗 (SAKK 17/04)：一项随机、国际、多中心 2 期试验。
Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.
4
Complete response and long-term survival in malignant pleural mesothelioma: case report.恶性胸膜间皮瘤的完全缓解和长期生存：病例报告。
Anticancer Res. 2012 Apr;32(4):1485-7.
5
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.胸膜内注射顺铂和丝裂霉素用于胸膜切除术后恶性间皮瘤的药代动力学研究。
J Clin Oncol. 1992 Jun;10(6):1001-6. doi: 10.1200/JCO.1992.10.6.1001.
6
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma.医学可切除的早期恶性胸膜间皮瘤管理计划中的化疗时机。
Expert Rev Respir Med. 2019 Jun;13(6):579-584. doi: 10.1080/17476348.2019.1607300. Epub 2019 Apr 23.
7
[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].恶性胸膜间皮瘤的临床病理特征与预后
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Nov;36(11):825-8.
8
Malignant pleural mesothelioma following chemotherapy for breast cancer.乳腺癌化疗后发生的恶性胸膜间皮瘤。
Anticancer Res. 2001 Jul-Aug;21(4B):3093-6.
9
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）成像在恶性胸膜间皮瘤管理中的当前及未来作用
Jpn J Radiol. 2016 Aug;34(8):537-47. doi: 10.1007/s11604-016-0555-1. Epub 2016 May 24.
10
[Management of malignant pleural effusion].[恶性胸腔积液的管理]
Rev Prat. 2007 Mar 15;57(5):513-23.
引用本文的文献
1
Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.安罗替尼治疗恶性纵隔间皮瘤：一例病例报告及文献复习
Front Oncol. 2023 May 16;13:1153233. doi: 10.3389/fonc.2023.1153233. eCollection 2023.
2
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.间皮瘤治疗的新见解：新兴途径与未来前景
Front Oncol. 2022 Jun 17;12:916839. doi: 10.3389/fonc.2022.916839. eCollection 2022.
3
Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27.胰岛素样生长因子2信使核糖核酸结合蛋白3通过下调p27促进恶性间皮瘤细胞的增殖。
Front Oncol. 2022 Jan 19;11:795467. doi: 10.3389/fonc.2021.795467. eCollection 2021.
4
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.DRREAM3R 方案：度伐鲁单抗联合化疗作为晚期胸膜间皮瘤一线治疗的 III 期随机试验。
BMJ Open. 2022 Jan 25;12(1):e057663. doi: 10.1136/bmjopen-2021-057663.
5
Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).化疗诱导 CDA 表达使耐药非小细胞肺癌细胞对 5'-去氧-5-氟胞苷（5'-DFCR）敏感。
J Exp Clin Cancer Res. 2021 Apr 19;40(1):138. doi: 10.1186/s13046-021-01938-2.
6
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.恶性胸膜间皮瘤中的循环表观遗传生物标志物：现状与批判性评价
Front Oncol. 2020 Apr 3;10:445. doi: 10.3389/fonc.2020.00445. eCollection 2020.
7
In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.顺铂和培美曲塞对恶性胸膜间皮瘤3D培养表型影响的体外特征分析
Cancers (Basel). 2019 Sep 27;11(10):1446. doi: 10.3390/cancers11101446.
8
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.非编码RNA与已获批的抗代谢药物（如吉西他滨和培美曲塞）在间皮瘤中的相互作用。
Noncoding RNA Res. 2018 Nov 4;3(4):213-225. doi: 10.1016/j.ncrna.2018.11.001. eCollection 2018 Dec.
9
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.载培美曲塞纳米粒靶向恶性胸膜间皮瘤细胞的体外研究。
Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019.
10
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.复发性胸膜间皮瘤的管理：尼达尼布联合化疗成功再次挑战治疗。
Clin Case Rep. 2018 Sep 4;6(10):2000-2004. doi: 10.1002/ccr3.1775. eCollection 2018 Oct.
本文引用的文献
1
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.一项舒尼替尼马来酸盐作为进展性恶性胸膜间皮瘤二线治疗的间歇性治疗的 II 期研究。
J Thorac Oncol. 2012 Sep;7(9):1449-56. doi: 10.1097/JTO.0b013e31825f22ee.
2
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.西地尼布治疗恶性间皮瘤患者的疗效：芝加哥大学二期联盟的一项二期临床试验。
Lung Cancer. 2012 Oct;78(1):76-80. doi: 10.1016/j.lungcan.2012.06.011. Epub 2012 Jul 23.
3
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.多中心、双盲、安慰剂对照、随机二期临床试验：吉西他滨/顺铂联合贝伐珠单抗或安慰剂治疗恶性间皮瘤患者。
J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4.
4
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.单药维持治疗晚期非小细胞肺癌的疗效Meta 分析。
Lung Cancer. 2012 Aug;77(2):331-8. doi: 10.1016/j.lungcan.2012.03.019. Epub 2012 Apr 28.
5
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.厄洛替尼和培美曲塞作为晚期非小细胞肺癌的维持治疗：系统评价和间接比较。
Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29.
6
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).凡德他尼治疗恶性胸膜间皮瘤：癌症和白血病组 B（CALGB30107）的 II 期试验。
Lung Cancer. 2012 Jun;76(3):393-6. doi: 10.1016/j.lungcan.2011.11.014. Epub 2011 Dec 22.
7
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.简要报告：尼洛替尼治疗恶性胸膜间皮瘤的 II 期研究。NCIC 临床试验组。
J Thorac Oncol. 2011 Nov;6(11):1950-4. doi: 10.1097/JTO.0b013e3182333df5.
8
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.厄洛替尼作为晚期非小细胞肺癌患者的维持治疗：三项随机试验的汇总分析。
Anticancer Drugs. 2011 Nov;22(10):1010-9. doi: 10.1097/CAD.0b013e328349d80d.
9
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.西地尼布治疗恶性胸膜间皮瘤的 II 期研究：SWOG S0509。
J Thorac Oncol. 2011 Nov;6(11):1938-45. doi: 10.1097/JTO.0b013e318229586e.
10
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.恶性胸膜间皮瘤二线化疗：回顾性多中心调查结果。
Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.
Zotero 插件